ENO2 and anemia: Bosch et al. recently published the results of a study of 11 TMs (CEA, PSA, AFP, CA 125, CA 15 − 3, CA 19 − 9, NSE, TAG-72, CYFRA 21 − 1, SCC, and gastrin-releasing-peptide precursor) in 4776 patients with suspicious clinical signs (fever, IWL, pain, mass, externalized bleeding, thrombosis, skin lesions, and pulmonary, digestive or neurologic symptoms), abnormal laboratory test results (anemia and other unspecified abnormalities) or radiological findings (fractures and bone lesions) [12].